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Abstract:  The aim of this study is to investigate the effect of the extracellular   
signal-regulated kinases 1/2 (ERK1/2) inhibitor, PD98059, on high blood pressure and 
related vascular changes. Blood pressure was recorded, thicknesses of renal small artery 
walls were measured and ERK1/2 immunoreactivity and erk2 mRNA in renal   
vascular smooth muscle cells (VSMCs) and endothelial cells were detected by 
immunohistochemistry and in situ hybridization in normotensive wistar kyoto (WKY) rats, 
spontaneously hypertensive rats (SHR) and PD98059-treated SHR.  Compared with   
normo-tensive WKY rats, SHR developed hypertension at 8 weeks of age, thickened renal 
small artery wall and asymmetric arrangement of VSMCs at 16 and 24 weeks of age. 
Phospho-ERK1/2 immunoreactivity and erk2 mRNA expression levels were increased in 
VSMCs and endothelial cells of the renal small arteries in the SHR. Treating SHR with 
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PD98059 reduced the spontaneous hypertension-induced vascular wall thickening. This 
effect was associated with suppressions of erk2 mRNA expression and ERK1/2 
phosphorylation in VSMCs and endothelial cells of the renal small arteries. It is concluded 
that inhibition of ERK1/2 ameliorates hypertension induced vascular remodeling in renal 
small arteries.  




Elevated arterial blood pressure is known to induce vascular structural change, which is termed as 
vascular remodeling (VR). VR mainly involves thickening and stenosis of the vascular wall. Previous 
studies have suggested that VR is not only a pathophysiological basis for the progression of 
hypertension but also for the development of other cardiovascular diseases [1]. Multiple factors, 
including blood pressure, oxidative stress, extracellular matrix and vascular smooth muscle cells 
(VSMCs) influence VR [2]. Modulating these factors could reduce or even reverse VR, thereby 
suppressing the progression of hypertension. For example, angiotensin-converting enzyme inhibitor 
(ACEI) has been shown to reduce blood pressure and to reverse the cardiovascular remodeling [3]. 
Similarly, anti-oxidants ameliorate VR through reducing production of free radicals and inhibiting 
oxidation of low-density lipoproteins [4]. Reversal of VR using pharmacological or genetic approaches 
may hold great potential for treating hypertension and hypertension-induced cardiovascular disorders.  
VSMCs remodeling in vascular wall during hypertension is mediated by activation of cell signal 
transduction pathways, such as protein kinase C (PKC) and mitogen-activated protein kinase (MAPK). 
Activation of these pathways results in proliferation of VSMC, eventually causing an increase in cell 
numbers or alteration of VSMC function [5]. Extracellular signal-regulated kinases 1 and 2 (ERK1/2) 
of MAPK family are core factors that regulate cell hypertrophy and proliferation [6,7]. Although, it is 
already known that ERK1/2 MAPK signal transduction cascade plays a key role in modulating VSMC 
proliferation, it remains unknown whether inhibition of ERK1/2 MAPK signaling pathway can 
ameliorate the VR process or even reduce blood pressure in hypertensive animals. The objective of this 
study was to explore the effects of ERK1/2 inhibitor PD98059 on VR and blood pressure in 
spontaneous hypertensive rats (SHR). The results revealed that while inhibition of ERK1/2 
ameliorated the progression of VR, it failed to reduce blood pressure of SHR. 
2. Results and Discussion 
2.1. Physiological Variable 
All animals survived to the pre-determined end-point. Body weight of non-treated hypertensive  
rats was significantly reduced compared with WKY rats (435.11 ± 41.86 g vs. 531.63 ± 43.38 g).  
The body weight of PD98059-treated hypertensive rats was 302.60 ± 13.87 g at 16-weeks and   
344.17 ± 22.23 g at 24-weeks, which was significantly lower than that of the age-matched WKY group Int. J. Mol. Sci. 2011, 12                
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(Figure 1a). Cardiac mass was determined in each animal and heart over body weight ratio was 
calculated. This ratio in SHR was 0.42 ± 0.20 at 16-weeks and 0.45 ± 0.20 at 24-weeks of age, which 
was significantly higher than that of the age matched WKY group (0.29 ± 0.10 and 0.28 ± 0.20 
for 16- and 24-weeks of age, respectively). Treatment with PD98059 moderately reduced the 
heart/body ratio at 16- and 24-weeks, although only the values at 24-weeks reached statistical 
significance (Figure 1b). 
Figure 1. Body weight (a) and heart and body weight ratio (b) in normotensive   
WKY rats, SHR and PD98059-treated SHR at 16 and 24 weeks of age.* P < 0.05 vs. WKY 
control and 
# P < 0.05 vs. SHR group. 
 
Arterial blood pressure remained normal in normotensive WKY rats at 16- and 24-weeks   
(102.50 ± 11.26 mmHg to 108.70 ± 8.48 mmHg, respectively). In SHR, blood pressure was normal at  
4 weeks (108.10 ± 7.09 mmHg), elevated at 8 weeks and remained hypertensive at 16- and 24-weeks 
compared with age-matched WKY controls (Figure 2) Treatment with PD98059 failed to reduce blood 
pressure, therefore, no difference in blood pressure was detected between the PD98059 group and  
age-matched SHR group. Int. J. Mol. Sci. 2011, 12                
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Figure 2. Arterial blood pressure in control SHR, PD98059-treated and normotensive 
WKY rats. Blood pressure increased in SHR and PD98059 groups. * P < 0.05 vs. SHR and 
PD98059 groups. 
 
2.2. Vascular Wall Morphology 
The structure of renal arteries and arterioles were examined on histological sections. The inner and 
outer diameters of renal arteries of transverse sections were measured and the thickness of the vascular 
wall was calculated by subtracting the inner diameter from the outer diameter. No abnormal arterial 
wall change was observed at WKY rats (Figure 3A,D). Renal arteriole structures were normal at   
4 weeks old SHR (data not shown). However, arteriole wall thickening, as reflected by a decreasing 
ratio of vascular inner to outer diameters, and luminal stenosis were observed in small arteries, 
especially the interlobar arteries, at 16 weeks old SHR (Figure 3B,G). At 24 weeks, additional changes, 
including proliferation and asymmetric arrangement of VSMC, as well as separation and breakage of 
internal elastic membrane were detected in arch arteries and interlobular arteries of the SHR   
(Figure 3E).Treatment with PD98059 failed to prevent the vascular structural alterations observed in 
SHR at 16 weeks (Figure 3C). However, PD98059 significantly ameliorated the thickening of the 
vascular wall at 24 weeks (Figure 3F), as reflected by the increased ratio of the inner to outer diameter 
of the vascular wall. Representative histograms of interlobar arteries are given in Figure 3A–F and the 
summarized ratio of renal interlobar arteries from 3 groups of rats is presented in Figure 3G. Int. J. Mol. Sci. 2011, 12                
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Figure 3. Morphological changes of renal interlobular arteries. (A–F) representative 
histograms of renal interlobular arteries. (A) normal morphology of WKY rats at 16 weeks 
of age group (▲); (B) increased thickness of interlobular artery wall in SHR at 16 weeks of 
age group (↑); (C) asymmetrically arranged VSMCs in PD98059-treated SHR at 16 weeks 
of age group (↑); (D) normal morphology of WKY rats at 24 weeks of age group (▲);  
(E) increased thickness of vessel wall in SHR at 24 weeks of age group (↑); (F) irregular 
arranged VSMCs and thickened wall in PD98059-treated SHR at 24 weeks of age (↑). 
H&E staining. Magnification, 400×. (G) Summarized ratio of the inner to outer diameter  
of the renal small arteries from 3 groups of animals. * P < 0.05 vs. WKY group and  
# P < 0.05 vs. SHR group. 
 
2.3. ERK Protein and mRNA Expression 
Phosphorylated ERK-1/2 in VSMCs of the renal small arterioles was detected by 
immunohistochemical staining. Representative histograms are given in Figure 4A–F and summarized 
data are presented in Figure 4G. As shown in these figures, there was no phospho-ERK1/2 Int. J. Mol. Sci. 2011, 12                
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immunoreactivity detected in normotensive WKY rats at either 16 or 24 weeks. A few positively 
stained renal VSMCs were observed in SHR at 16 weeks and the number increased at 24 weeks. As 
shown, the ratio of phospho-ERK1/2 positive-stained VSMCs to total VSMCs significantly increased 
at both 16 and 24 weeks of age compared with normotensive WKY rats. Treatment of PD98059 in 
SHR group significantly reduced the number of phospho-ERK1/2 positive renal small artery VSMCs 
at both 16 and 24 weeks of age (P < 0.05). 
Figure 4. Phospho-ERK1/2 immunohistochemistry in VSMCs of interlobar arterioles.   
A–F, representative ERK1/2 immunohistostaining in VSMCs. (A) no expression of 
phospho-ERK1/2 in WKY at 16 weeks of age group (▲); (B) increased expression of 
phospho-ERK1/2 in SHR at 16 weeks of age group (↑); (C) reduced expression of   
phospho-ERK1/2 in PD98059-treated SHR at 16 weeks of age group (↑); (D) no 
expression of phospho-ERK1/2 in WKY rats at 24 weeks of age group (▲); (E) increased 
expression of phospho-ERK1/2 in SHR at 24 weeks of age group; (F) reduced expression 
of phospho-ERK1/2 VSMC except distal renal tubule (↑) in PD98059-treated SHR at 
24  weeks of age group (▲). DAB visualized, slight hematoxylin counterstaining. 
Magnification, 400×. G, Summary of phospho-ERK1/2 positively stained VSMCs in the 
small renal arteries. * P < 0.05, vs. WKY group; 
# P < 0.05, vs. SHR group. 
 Int. J. Mol. Sci. 2011, 12                
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Similar changes were also observed in endothelial cells of the renal small arteries. Therefore, few or 
no immunoreactivity of phospho-ERK1/2 was detected in normotensive WKY rats at 16 and 24 weeks. 
The number of phospho-ERK1/2 positive endothelial cells increased significantly at 16 and   
24 weeks in SHR animals. Treatment with PD98059 in SHR significantly reduced the number of  
phospho-ERK1/2 positive cells at 16 and 24 weeks. A set of representative histograms showing 
phospho-ERK1/2 immunohistology in endothelial cells is given in Figure 5A–F and summarized data 
are presented in Figure 5G.  
Figure 5. Phospho-ERK1/2 immunohistochemistry in endothelial cells of the small renal 
arteries (A–F). (A) no expression of phospho-ERK1/2 in WKY rats at 16 weeks of age 
group (▲); (B) increase in number of phospho-ERK1/2 positive cells in SHR at 16 weeks 
of age group (↑); (C) reduction in number of phospho-ERK1/2 positive cells in   
PD98059-treated SHR at 16 weeks of age group (↑); (D) no expression of phospho-ERK1/2 
in WKY rats at 24 weeks of age group (▲); (E) increase in number of phospho-ERK1/2 
positive cells in SHR at 24 weeks of age group; (F) significantly decrease in number of 
phospho-ERK1/2 positive cells in PD98059-treated SHR at 24 weeks of aged group (↑). 
DAB was used as substrate. Hematoxylin counterstaining. Magnification, 400×.   
(G) summarized data showing number of phospho-ERK1/2 positive endothelial cells of the 
small renal arteries. * P < 0.05 vs. WKY group and 
# P < 0.05 vs. SHR group. 
 Int. J. Mol. Sci. 2011, 12                
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Erk2 mRNA expression was detected using in situ hybridization. The results showed that little or 
non-detectable mRNA expression in WKY rats at 16 and 24 weeks of age (Figure 6A,D). Erk2 mRNA 
expression was markedly enhanced in VSMCs of the small renal arteries of SHR at 16 and 24 weeks 
(Figure 6B,E), as well as in epithelial cells of renal distal convoluted tubule (data not shown). Treating 
SHR with PD98059 significantly suppressed the erk2 mRNA expression in the VSMCs of the small 
renal arteries (Figure 6C,F). A set of histograms showing erk2 in situ hybridization in small renal 
arteries are given in Figure 6A–F and the summarized data are presented in Figure 6G. 
Figure 6. A set of histograms showing in situ hybridization of erk2 in VSMCs of small 
renal arteries. Little to none erk2 mRNA expression (▲) was observed in WKY rats at  
16 and 24 weeks (A,D). Marked increase of erk2 mRNA expression (↑) was detected in 
SHR at 16 and 24 weeks of age group (B,E).  Erk2 mRNA was reduced in   
PD98059-treaetd SHR (↑) at 16 and 24 weeks of age group(C,F). Arrow heads denote 
negative cells and arrows denote positive cells. DAB was used as substrate. Sections were 
counterstained with hematoxylin. Magnification, 400×. (G) summarized bar graph showing 
number of in situ phospho-ERK1/2 VSMCs over total observed VSMCs in three groups of 
animals at 16 and 24 weeks. * P < 0.05 vs. WKY group and 
# P < 0.05 vs. SHR group. 




Chronic hypertension changes the dimensions and properties of arterial wall. These changes include 
proliferation of VSMCs and thickening of arterial wall (for review see [8]). One of the molecular 
mechanisms responsible for vascular remodeling is activation of ERK1/2, which causes VSMCs to 
proliferated and deposit collagen type I on microvessels [9,10]. Our results showed that spontaneous 
hypertension increased the thickness of renal small artery wall and the proliferation of VSMCs. In 
agreement with previous studies [7,11], phosphor-REK1/2 MAPK immunoreactivity enhanced in renal 
VSMCs and endothelial cells. Inhibition of ERK1/2 using PD98059 suppressed ERK1/2 
immunoreactivity and ameliorated the thickening of vascular wall in 24 weeks SHR. Our study 
demonstrated that inhibition of ERK1/2 kinases could significantly suppress the progression of 
vascular remodeling in spontaneous hypertensive animals. 
In the present study, SHR developed hypertension at 8 weeks of age, which is in agreement with 
previous published report [7,12] Hypertension increases peripheral blood vessels resistance through 
vascular remodeling, a process involving VSMC proliferation, hypertrophy, blood vessel compliance 
reduction and the narrow vessel lumen. The decreased body weight in SHR compared with WKY rats 
in the present study reflects the general deterioration of health associated with hypertension. The 
increased heart to body mass ratio in SHR reflects myocardial hypertrophy in response to increase 
cardiac after-load caused by high blood pressure. 
VSMCs regulate vascular structure and reactivity under physiological and pathological   
conditions [13–15]. Normally, VSMCs are in a non-proliferative state. After being stimulated by 
stretch or high blood pressure, VSMCs proliferate, vascular smooth muscle layer become thicker and 
vascular lumen size decreases. As results, vascular resistance increases [16].
 Several factors regulate 
the VSMCs, including platelet-derived growth factor, insulin-like growth factor, norepinephrine, 
endothelin angiotensin II and cytokines [3,5–7,17]. These factors are released during vascular injury. 
They convert VSMCs from quiescent state to active synthetic state [18,19]. Activated VSMCs 
synthesize and release vasoactive factors, growth factors and extracellular matrix proteins, which cause 
VSMC hypertrophy, proliferation and migration, excessive accumulation of extracellular matrix,   
and eventually, vascular remodeling [20,21]. Abnormal proliferation of VSMC is a common 
pathophysiological change observed in hypertension [21].
 The increase in number of VSMCs and 
narrowingness of renal arterioles observed in the present study reflect vascular remodeling induced by 
hypertension. Such remodeling is likely mediated by ERK1/2. 
Activation of ERK1/2 by phosphorylation causes cell proliferation and growth [22–24]. ERK1/2 is 
activated by MAPK kinase (MEK) and the latter is activated by Raf-1. The ERK1/2 MAPK signaling 
pathway plays an important role in cell proliferation and extracellular matrix deposition during 
hypertensive cardiovascular remodeling [25].
 ERK1/2 activation stimulates vascular smooth muscle 
cell hypertrophy and hyperplasia, which lead to an increase in peripheral resistance and elevation of 
blood pressure. In present study, ERK1/2 phosphorylation increased significantly in the endothelial 
cells and VSMCs of the small renal arterioles in SHR at 16 and 24 weeks, suggesting that ERK1/2 was 
involved in the hypertension-induced vascular remodeling. The involvement of ERK1/2 in 
hypertension-induced renal vascular remodeling was further supported by the results obtained from 
ERK1/2 inhibitor studies.  Int. J. Mol. Sci. 2011, 12                
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Treating SHR with ERK1/2 inhibitor PD98059 significantly reduced the number of VSMCs and 
increased the lumen size of small renal arterioles after 4–8 weeks. These effects are associated with 
suppression of phospho-ERK1/2 levels in the endothelial cells and VSMCs. Since inhibition of 
ERK1/2 resulted in suppression of vascular remodeling in SHR, the results may suggest that 
hypertension-induced vascular remodeling is mediated through ERK1/2 signaling pathways. 
Furthermore, our data also suggest that inhibition of ERK1/2 ameliorates hypertension-induced 
vascular remodeling. Inhibition of ERK1/2 has been shown to reduce blood pressure in leptin-induced 
hypertension [26] and in endothelin-induced hypertension [27]. Our results showed that inhibition of 
ERK1/2 failed to lower blood pressure in SHR animals, indicating PD98059 may not be used as a 
blood pressure lowering drug. However, since PD98059 decelerated the development of the renal 
vascular remodeling, it may be effective in reducing the progression of hypertension and in preventing 
further blood pressure increase in SHR animals. Combination of blood lowering drug with ERK 
inhibitor may be beneficial to hypertensive patients. 
3. Materials and Methods 
3.1. Animals and Reagents 
Sixty-four SHR rats (16 males and 16 females) and 8 normal WKY (4 males and 4 females) were 
purchased from Vitalriver Experimental Animal Technology Co., Ltd. (Beijing, China). All animal 
care and procedures were in strict accordance with the China Laboratory Animal Use Regulations and 
were approved by the Institutional Animal Care and Use Committee at Ningxia Medical University, 
Yinchuan, China. Efforts were made to minimize animal numbers and stress. Monoclonal   
anti-phospho-ERK1/2 antibody (Cell Signaling), ERK1/2 inhibitor PD98059 (Merck), Streptavidin-
biotin complex kits (Zymed), and protein markers were purchased from Wuhan Boster Biological 
Engineering Limited (Wuhan, China).  
3.2. Animal Treatments 
Animals at 4 weeks of age were randomly divided into 3 groups: (i) Normotensive WKY rats 
(WKY group, n = 8), (ii) SHR control group (SHR group, n = 16), and (iii) PD98059-treated SHR 
group (PD98059 group, n = 16). Animals in the treatment group were intraperitoneally injected with 
PD98059 (10 mg/kg) once a day for 5 days per week, while those in SHR group and WKY group were 
injected with 0.9% saline. The injections were lasted for 12 or 20 weeks. Blood pressure was 
monitored once a week using a tail BP-6 animal non-invasive blood pressure device (Chengdu China) 
during the experimental period. Animals were anesthetized using intraperitoneally injection of   
4% sodium pentobarbital (30 mg/kg) at the ages of 16 or 24 weeks. The right kidney was harvested. 
The kidneys were placed in 4% paraformaldehyde for hematoxylin and eosin staining, in situ 
hybridization and immunohistochemistry.  
3.3. Immunohistochemistry 
Immunohistochemistry was performed on kidney sections (5 μm thickness). The sections were 
treated with 3% H2O2 for 10 minutes at room temperature to quench endogenous peroxidase activity. Int. J. Mol. Sci. 2011, 12                
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Antigen retrieval was performed by placing the sections in citrate buffer and heated for 30-s in a 
microwave oven before nonspecific binding sites were blocked in 5% bovine serum albumin (BSA) in 
PBS/0.2% TX-100 for 30 min. The sections were incubated in primary anti-phospho-ERK1/2 antibody 
(1:400 dilution) overnight at 4 °C. After 3 washes in phosphate buffered saline (PBS), the sections 
were then incubated with biotinylated secondary antibody for 30 min at room temperature. The a 
vidin-biotin complex (ABC) technique was then applied. Sections were stained in a horseraddish 
peroxidase substrate solution (diaminobenzidine), counter-stained with hematoxylin and mounted on 
glass slides. The sections were scanned using a computer-assisted imaging system (Zeiss LSM5 Image 
Examiner software). The inner and outer diameters of small renal arteries were measured using image 
analysis software (Zeiss LSM5 Image Examiner software). Numbers of ERK1/2 positive stained 
VSMCs and endothelial cells were counted on a 50 mm
2 on each section using a grid ruler placed in 
the optical lens and the result is presented as a ratio of positive cells to total cells in the area. 
3.4. In Situ Hybridization 
Digoxygenin-labeled riboprobes that were synthesized by Wuhan Boster Biological Engineering 
Limited (Wuhan China) were used for the detection of rat ERK2 mRNA. The oligonucleotide probe 
sequences are as follows: Sense: 5′-AGATG GTCCG CGGGC AGGTG TTCGA CGTAG-3′ and 
antisense: 5′-AAAAT AAGGT GCCAT GGAAC AGGTT GTTCC-3′.  The probe specificity was 
confirmed by BLAST software testing. 
After deparaffinizaton, rehydration and quench of endogenous peroxidase activity by 3.0% H2O2 at 
room temperature for 5–10 min, the sections were treated with pepsin freshly dissolved in 3% citric acid 
solution for 25 min at 37 °C incubator. Followed fixed with 1% paraformaldehyde for 10 min at room 
temperature and incubated with 20 μL of pre-hybridization solution for 3 hours at 38–42 °C, the 
sections were incubated with sense or anti-sense (control) riboprobe hybridization solution overnight  
at 38–42 °C. The reaction was stopped by dropping blocking solution on the slides. Biotinylated 
mouse anti-digoxigenin was applied on the sections for 60 min at 37 °C, and followed by reaction of 
SABC. Biotin-peroxidase complex was applied and diaminobezidine was used as a substrate. The 
sections were counterstained with hematoxylin and mounted. The images were analyzed under a 
microscope and presented as a ratio of positively stained cells to total cells for a 50 mm
2 area. 
3.5. Statistical Analysis 
The values were expressed as means ± SEM. ANOVA followed by Tukey’s test was used to 
analyze the differences among 3 groups. Statistical significance was determined as P < 0.05. 
4. Conclusion 
Our study showed that spontaneous hypertension increased the thickness of the renal arterial wall  
at 16 and 24 weeks compared with normotensive WKY rats. In addition, hypertension increased both 
phosphorylation of ERK1/2 and mRNA expression of erk2 in renal small arterial endothelial cells and 
VSMCs at 16 and 24 weeks of age. Furthermore, our results demonstrated that inhibition of ERK1/2 
activity by PD98059 in hypertensive rats significantly reduced the erk2 mRNA expression,   Int. J. Mol. Sci. 2011, 12                
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inhibited ERK1/2 phosphorylation and ameliorated the hypertension-induced vascular alterations. 
These results suggest that hypertension-induced renal vascular remodeling is likely mediated by the 
ERK1/2 signaling pathway. 
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